Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutathione plus vitamin C preconditioning to reduce hepatic ischemia-reperfusion injury after subtotal hepatectomy
ChiCTR2100041840Phase 4Recruiting
- Sponsor
- Taizhou People's Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of glutathione and ascorbic acid in hepatic ischemia-reperfusion injury (HIRI) (2 arms), sponsored by Taizhou People's Hospital. Primary endpoints: Alanine aminotransferase, Aspartate aminotransferase and 9 more. Started Jan 2021; status: recruiting.
02
Drugs
glutathioneascorbic acid
03
Conditions
hepatic ischemia-reperfusion injury (HIRI)
Beyond the preview
Go deeper on ChiCTR2100041840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041840.